Aldeyra Therapeutics Inc at Citi BioPharma Conference (Virtual) Transcript
Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. This is our panel on next-generation retinal therapeutics. It's my great pleasure to have with me today from Aerie Pharma, Vince Anido, who's the Chairman and CEO; from Aldeyra Therapeutics, Todd Brady, the CEO; and from Opthea Limited in Australia, Megan Baldwin, the CEO.
So welcome, everyone. Thank you so much for taking the time to participate in our panel. I think as a starting point, since some of the listeners may be less familiar with your companies, why don't we just do a 2- to 3-minute intro for each of you as to what you're focused on, what the pipeline is at your company and maybe 1 or 2 of the key upcoming data points.
So maybe, Todd, do you want to kick it off?
Thanks, Yigal, and thanks for having us on the conference today. Aldeyra is an immunology company at heart. We've started out in the eye,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |